Physician profile

Ealon Joelson

Neurology (Psychiatry & Neurology) · Palo Alto, CA

NPI 1770658841

$10,980.07

in general payments reported to CMS, 2019-2025

39 companies · $3,107 in 2025

The $3,107 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).

See the full distribution for Neurology (Psychiatry & Neurology)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$6,976.64
Education$375.88

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $2,601.05 2021-2025
Teva Pharmaceuticals USA, INC. $1,021.94 2021-2025 Austedo Xr, Austedo Xr, Austedo
Impel Pharmaceuticals INC. $662.26 2022-2023 Trudhesa
Ucb, INC. $598.59 2019-2025 Rystiggo, Zilbrysq
Alexion Pharmaceuticals, INC. $579.74 2019-2025 Ultomiris
Emd Serono, INC. $510.05 2019-2020
Pfizer INC. $485.36 2019-2025
Sk Life Science, INC. $469.26 2021-2025 Xcopri
Neurocrine Biosciences, INC. $372.71 2024-2025 Ingrezza
Novartis Pharmaceuticals Corporation $361.15 2019-2025
Allergan, INC. $306.55 2019-2021
Neurelis, INC. $306.51 2024-2025 Valtoco
Mdd US Operations, LLC $281.34 2023-2025 Gocovri
Amgen INC. $251.80 2019-2025 Uplizna
Biogen, INC. $213.07 2021-2025 Vumerity, Tysabri
Show all 39 companies
CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $177.24 2020-2024 Emgality, Reyvow
Biohaven Pharmaceuticals, INC. $167.90 2020-2021
Lundbeck LLC $150.76 2021-2025 Rexulti, Vyepti
Acorda Therapeutics, INC $124.11 2019-2024 Inbrija
Kyowa Kirin, INC. $119.26 2020-2024 Nourianz
Biohaven Pharmaceutical Holding Company LTD. $114.74 2022
Avanir Pharmaceuticals, INC. $108.42 2020
Sunovion Pharmaceuticals INC. $108.42 2019-2021
Amneal Pharmaceuticals LLC $106.44 2019-2025 Rytary, Crexont, Unithroid
Merz Pharmaceuticals, LLC $98.67 2021-2025 Xeomin, Inbrija
Sumitomo Pharma America, INC. $93.26 2023 Aptiom
Acadia Pharmaceuticals INC $83.58 2019-2021
Tg Therapeutics, INC. $75.18 2025
Genentech USA, INC. $67.80 2023-2025 Ocrevus, Enspryng, Ocrevus Zunovo
Otsuka America Pharmaceutical, INC. $61.68 2025 Rexulti
Supernus Pharmaceuticals, INC. $53.86 2019-2020
Adamas Pharmaceuticals, INC. $47.82 2020-2021
Banner Life Sciences, LLC $44.71 2024
Eisai INC. $33.26 2019
Horizon Therapeutics Plc $30.76 2022
Merz North America, INC. $27.81 2019
Otsuka Pharmaceutical Development & Commercialization, INC. $27.69 2025 Rexulti
Axsome Therapeutics, INC. $22.33 2025 Symbravo
Csl Behring $12.99 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ealon Joelson

$10,980.07

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $3,107 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).

https://glasscript.com/doctor/80023/ealon-joelson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.